Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Feb;27(2):257–262. doi: 10.1128/aac.27.2.257

Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro.

R Anderson
PMCID: PMC176249  PMID: 3857019

Abstract

The effects of the antileprosy agents clofazimine and dapsone (1 to 10 micrograms/ml) on the spontaneous and stimulated release of prostaglandin E2 (PG E2) by human polymorphonuclear leukocytes (PMNL) in vitro have been investigated. PMNL were obtained from normal adult volunteers and three patients with leprosy (two borderline lepromatous and one subpolar lepromatous leprosy). The synthetic chemotactic tripeptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) at a concentration of 10(-7) M was used as the stimulant of PG E2 synthesis. None of the test agents at the concentrations used inhibited the binding of radiolabeled FMLP to PMNL. However, dapsone at 5 and 10 micrograms/ml inhibited the spontaneous and FMLP-induced release of PG E2 by PMNL. Clofazimine, on the other hand, significantly increased both the spontaneous and the FMLP-induced synthesis of PG E2 by PMNL. The enhancing effects of clofazimine on FMLP-mediated synthesis of PG E2 were particularly striking and were observed at concentrations of 1 to 10 micrograms of the drug per ml. Measurements of PMNL spontaneous and FMLP-induced synthesis of PG E2 in the presence of both clofazimine and dapsone (5 micrograms/ml) indicated that the two drugs are mutually antagonistic. PMNL from both normal control subjects and patients with leprosy were equally sensitive to these effects of clofazimine and dapsone. The immunostimulatory and immunosuppressive properties of dapsone and clofazimine, respectively, may be related to the opposite effects of these agents on PG E2 synthesis in human leukocytes.

Full text

PDF
258

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. O., Young E., McFadyen T., Fraser N. G., Duguid W. P., Meredith E. M. Absorption and excretion of 35S dapsone in dermatitis herpetiformis. Br J Dermatol. 1970 Dec;83(6):620–631. doi: 10.1111/j.1365-2133.1970.tb15756.x. [DOI] [PubMed] [Google Scholar]
  2. Anderson R., Gatner E. M., van Rensburg C. E., Grabow G., Imkamp F. M., Kok S. K., van Rensburg A. J. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1981 Apr;19(4):495–503. doi: 10.1128/aac.19.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BARRY V. C., BELTON J. G., CONALTY M. L., DENNENY J. M., EDWARD D. W., O'SULLIVAN J. F., TWOMEY D., WINDER F. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957 May 18;179(4568):1013–1015. doi: 10.1038/1791013a0. [DOI] [PubMed] [Google Scholar]
  4. Brandt L., Svensson B. Stimulation of macrophage phagocytosis by clofazimine. Scand J Haematol. 1973;10(4):261–264. doi: 10.1111/j.1600-0609.1973.tb00070.x. [DOI] [PubMed] [Google Scholar]
  5. Cline M. J. Drug potentiation of macrophage function. Infect Immun. 1970 Nov;2(5):601–605. doi: 10.1128/iai.2.5.601-605.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fischer A., Durandy A., Griscelli C. Role of prostaglandin E2 in the induction of nonspecific T lymphocyte suppressor activity. J Immunol. 1981 Apr;126(4):1452–1455. [PubMed] [Google Scholar]
  7. Gatner E. M., Anderson R., van Remsburg C. E., Imkamp F. M. The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals. Lepr Rev. 1982 Jun;53(2):85–90. [PubMed] [Google Scholar]
  8. Goodwin J. S., Selinger D. S., Messner R. P., Reed W. P. Effect of indomethacin in vivo on humoral and cellular immunity in humans. Infect Immun. 1978 Feb;19(2):430–433. doi: 10.1128/iai.19.2.430-433.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Imkamp F. M. A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663). Lepr Rev. 1968 Jul;39(3):119–125. doi: 10.5935/0305-7518.19680022. [DOI] [PubMed] [Google Scholar]
  10. Leiker D. L. Chemotherapy of leprosy. Int J Lepr Other Mycobact Dis. 1971 Apr-Jun;39(2):462–466. [PubMed] [Google Scholar]
  11. Pfaltzgraff R. E. The control of neuritis in leprosy with clofazimine. Int J Lepr Other Mycobact Dis. 1972 Oct-Dec;40(4):392–398. [PubMed] [Google Scholar]
  12. Prokesch R. C., Hand W. L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1982 Mar;21(3):373–380. doi: 10.1128/aac.21.3.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ramu G., Sengupta U., Desikan K. V. Influence of sulphone therapy on lepromin reaction. Lepr Rev. 1980 Sep;51(3):207–214. doi: 10.5935/0305-7518.19800018. [DOI] [PubMed] [Google Scholar]
  14. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  15. Schulz E. J. Forty-four months' experience in the treatment of leprosy with clofazimine (Lamprene (Geigy)). Lepr Rev. 1971 Sep;42(3):178–187. doi: 10.5935/0305-7518.19710021. [DOI] [PubMed] [Google Scholar]
  16. Vischer W. A. The experimental properties of G 30 320 (B 663)--a new anti-leprotic agent. Lepr Rev. 1969 Apr;40(2):107–110. doi: 10.5935/0305-7518.19690021. [DOI] [PubMed] [Google Scholar]
  17. Waters M. F. The treatment of leprosy. Tubercle. 1983 Sep;64(3):221–232. doi: 10.1016/0041-3879(83)90018-1. [DOI] [PubMed] [Google Scholar]
  18. Yawalkar S. J., Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev. 1979 Jun;50(2):135–144. doi: 10.5935/0305-7518.19790020. [DOI] [PubMed] [Google Scholar]
  19. Zurier R. B. Prostaglandins, immune responses, and murine lupus. Arthritis Rheum. 1982 Jul;25(7):804–809. doi: 10.1002/art.1780250718. [DOI] [PubMed] [Google Scholar]
  20. Zurier R. B., Quagliata F. Effect of prostaglandin E 1 on adjuvant arthritis. Nature. 1971 Dec 3;234(5327):304–305. doi: 10.1038/234304a0. [DOI] [PubMed] [Google Scholar]
  21. van Rensburg C. E., Gatner E. M., Imkamp F. M., Anderson R. Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1982 May;21(5):693–697. doi: 10.1128/aac.21.5.693. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES